Investigational drug · Phase 3
Domvanalimab
Also called: AB154, GS-0154, DOM
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
6 still active
All registered trials
22
Any phase or sponsor naming "Domvanalimab"
First trial start
2018
Aug 13, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Domvanalimab", any sponsor or status.
- Phase 217
Conditions studied
As listed on its trial records.
- Lung Cancer
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Advanced or Metastatic Non-Small-Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer
- Metastatic Urothelial Cancer
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Domvanalimab" as an intervention, largest first.
Arcus Biosciences, Inc.Industry
NCT05568095 · 1,040 participants · Start Nov 21, 2022 · Primary completion Aug 28, 2026
Drug: Domvanalimab; Zimberelimab and 5 more · For: Advanced Upper Gastrointestinal Tract Adenocarcinoma
Sites: Los Angeles, California; Orange, California; Santa Monica, California · 168 sites in all
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502237 · 1,021 participants · Start Oct 12, 2022 · Primary completion Jun 2028
Drug: Zimberelimab; Domvanalimab and 6 more · For: Non-small Cell Lung Cancer
Sites: Whittier, California; Washington D.C., District of Columbia; Tampa, Florida · 186 sites in all
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05211895 · 791 participants · Start Feb 18, 2022 · Primary completion Aug 10, 2026
Drug: Durvalumab; Domvanalimab · For: Non-Small Cell Lung Cancer
Sites: Chandler, Arizona; Phoenix, Arizona; Fountain Valley, California · 226 sites in all
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT03547973 · 502 participants · Start Aug 13, 2018 · Primary completion Apr 2030
Drug: Sacituzumab Govitecan-hziy; Pembrolizumab and 7 more · For: Metastatic Urothelial Cancer
Sites: Tucson, Arizona; San Francisco, California; Littleton, Colorado · 128 sites in all
- Study With Various Immunotherapy Treatments in Participants With Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05676931 · 400 participants (planned) · Start Feb 21, 2023 · Primary completion Dec 2027
Drug: Domvanalimab; Quemliclustat and 3 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; La Jolla, California; Hollywood, Florida · 53 sites in all
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT05329766 · 332 participants · Start Jun 10, 2022 · Primary completion Sep 7, 2026
Drug: Domvanalimab; Quemliclustat and 4 more · For: Gastrointestinal Tract Malignancies
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 43 sites in all
- Study of Novel Treatment Combinations in Patients With Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05633667 · 192 participants · Start Mar 16, 2023 · Primary completion Sep 2029
Drug: Zimberelimab (ZIM); Domvanalimab (DOM) and 9 more · For: Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer
Sites: Tucson, Arizona; Fort Wayne, Indiana; Lexington, Kentucky · 89 sites in all
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04736173 · 169 participants · Start Feb 8, 2021 · Primary completion Sep 17, 2026
Drug: Domvanalimab; Zimberelimab and 4 more · For: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer and 1 more
Sites: Columbus, Georgia; Kingwood, Texas; Blacksburg, Virginia · 38 sites in all
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT04262856 · 151 participants · Start May 28, 2020 · Primary completion Jul 9, 2025
Drug: Domvanalimab; Etrumadenant and 1 more · For: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer and 1 more
Sites: Birmingham, Alabama; Whittier, California; Englewood, Florida · 44 sites in all
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Pivotal-lookingNot yet recruiting
Hospices Civils de LyonAcademic, hospital or other
NCT07337447 · 122 participants (planned) · Start Apr 2026 · Primary completion Apr 2029
Drug: FOLFIRI + Zimberelimab + Domvanalimab; FOLFIRI (standard of care) · For: Carcinoma, Neuroendocrine
Sites: Amiens, France; Bobigny, France; Caen, France · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Interfacial and molecular characteristics associated with persistent organic matter in mature landfill leachate.
Liu L, Liu B, Zhang Y, et al. · Waste Manag 2027
- Mechanistic insights into ultrafiltration fouling mitigation by coagulation pretreatment in livestock biogas slurry treatment.
Xie W, Luo A, Tang P, et al. · Waste Manag 2027
- Enhancing humification enzymatic activity and antibiotic resistance gene attenuation in aerobic composting of sewage sludge and food waste: The role of calcium oxide amendment.
Jabbi ES, Ahmed I, Zhang D, et al. · Waste Manag 2027
- Planktonic bacterial motility mediates dissolved organic matter transformation in inland waters: Insights from metatranscriptomics and carbon isotopic evidence.
Yang J, Li W, Wang B, et al. · Microbiol Res 2027
- Maximizing molecular coverage in ultrahigh-resolution orbitrap analysis of marine dissolved organic matter using two-stage design-of-experiments strategy.
Flahou T, Vailhen D, Bridoux MC · Talanta 2027
- Aquatic macrophyte coverage and organic matter enrichment drive greenhouse gas (CO2, CH4, N2O) emissions in aquaculture ponds.
Geng S, Teshaeva MZ, Chen X, et al. · Environ Res 2026
Also in development for Lung Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- zipalertinibTAS6417, CLN-081Phase 34 trials
Taiho Oncology, Inc. · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- TilesizumabBGB-108Phase 31 trial
Qilu Pharmaceutical Co., Ltd. · Lung Cancer
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- HRS-4508Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Solid Tumor, Lung Cancer
- JDQ443OpnurasibPhase 23 trials
Novartis · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.